Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05174637 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of FDA018-ADC in Patients With Advanced Solid Tumors

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: 2 to 5
    • Secondary endpoints: 9 to 8
    • Study description expanded, about 47 words
    v5
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v4
  3. 2 versions Re-verified since May 9, 2023, no change to tracked fieldsv2-v3
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and efficacy of FDA018-ADC in patients with advanced/metastatic solid tumors.
Trial Details
NCT Number NCT05174637
Lead Sponsor Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Advanced/ Metastatic Solid Tumors
Enrollment 78 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov